12 October 2021 in Cancer Cell International
Background: Exosome-mediated crosstalk between cancer cells and immune cells contributes to tumor growth. In this study, we investigated the mechanism underlying the exosome-mediated immune escape of colorectal cancer (CRC) cells from natural killer (NK) cells via the transfer of long noncoding RNAs (lncRNAs). Methods: An epithelial–mesenchymal transition (EMT) model of SW480 cells was established by transforming growth factor beta (TGF-β), followed by the assessment of the effect of EMT-derived exosomes (EMT-exo) on the functions of NK cells. RNA sequencing was performed to identify exosomal lncRNAs and target genes. The function of exosomal lncRNAs in tumor growth was further verified in vivo. Results: EMT-exo suppressed the proliferation, cytotoxicity, IFN-γ production, and perforin-1 and granzyme B secretion of NK cells. RNA sequencing revealed that SNHG10 expression was upregulated in EMT-exo compared with that in non-EMT-exo. Moreover, SNHG10 expression was upregulated in tumor tissues in CRC, which was associated with poor prognosis. Overexpression of SNHG10 in exosomes (oe-lnc-SNHG10 exo) significantly suppressed the viability and cytotoxicity of NK cells. Transcriptome sequencing of NK cells revealed that the expression levels of 114 genes were upregulated in the oe-lnc-SNHG10 exo group, including inhibin subunit beta C (INHBC), which was involved in the TGF-β signaling pathway. Si-INHBC treatment abrogated the effect of oe-lnc-SNHG10 exo on NK cells. oe-lnc-SNHG10 exo induced tumor growth and upregulated INHBC expression in mice and downregulated the expression of perforin, granzyme B, and NK1.1 in tumor tissues. Conclusions: The CRC cell-derived exosomal lncRNA SNHG10 suppresses the function of NK cells by upregulating INHBC expression. This study provides evidence that exosomal lncRNAs contribute to immune escape by inducing NK cell inhibition and proposes a potential treatment strategy for CRC.
1 May 2017 in Urologic Oncology: Seminars and Original Investigations
30 May 2013 in Clinical Cancer Research
Purpose: As a newly added member of the UNC5H receptors, the function of UNC5D/H4 in tumorigenesis remains poorly defined. The aim of this study was to examine the expression of UNC5D in primary renal cell carcinomas (RCC), analyze the mechanisms responsible for its downregulation in RCC, and assess its functional relevance to tumor growth and migration. Experimental Design: Forty-four paired primary RCCs and corresponding adjacent noncancerous tissues were collected. The mRNA and protein expression level of UNC5D was assessed by reverse transcriptase-PCR, real-time PCR, or immunohistochemistry. Epigenetic alterations in UNC5D promoter and LOH in the UNC5D locus were also analyzed. Ectopic expression of UNC5D in renal cancer cells with silenced expression of UNC5D was used for analysis of the biologic functions of UNC5D. Results: UNC5D expression was attenuated in multiple carcinoma cell lines including renal cancer cells. Similar reduction was also observed in primary RCC tissues as compared with paired adjacent noncancerous tissues. Methylation-specific PCR showed hypermethylation in UNC5D promoter in a significant proportion (18 of 44) of tumor tissue (40.9%). LOH of UNC5D was observed in 13 of 44 patients with RCCs (29.5%). Restoration of UNC5D expression in renal cancer cells significantly inhibited cell proliferation, anchorage-dependent and -independent growth, as well as migration and invasion, whereas knockdown of UNC5D promoted cell growth. Furthermore, ectopic expression of UNC5D induced G2–M cell-cycle arrest. Conclusions: UNC5D is a functional tumor suppressor that is frequently downregulated in RCCs due to promoter hypermethylation and LOH. Clin Cancer Res; 19(11); 2883–92. ©2013 AACR.
18 December 2021 in Clinical Epigenetics
Background: Deregulated methylation of tumor suppressor genes is a hallmark event in colorectal cancer (CRC) carcinogenesis. UNC5 receptors, down-regulated in various human malignancies due to epigenetic alterations, have been proposed as putative tumor suppressor genes. In this study, we focused on the methylation-mediated inhibition of UNC5 receptors and the associated clinical significance in CRC. Methods: Methylation and expression analysis was performed in TCGA datasets. And the results were confirmed in vitro in CRC cell lines treated with 5-aza-deoxycytidine. Then, the expression and epigenetic alterations of UNC5 receptors were evaluated in clinical specimens. Moreover, the diagnostic and prognostic values of the methylation alterations were also analyzed. Results: Methylation-mediated repression was observed in UNC5C and UNC5D, but not in UNC5A and UNC5B, which was confirmed in CRC cell lines. Except for UNC5B, significantly elevated methylation was observed in UNC5A, UNC5C, and UNC5D in CRC. The discrimination efficiency of the three receptors was comparable with that of SEPT9. Kaplan–Meier curve survival analysis showed that hypermethylation of UNC5A, UNC5C and UNC5D was associated with poor progression-free and overall survival. Moreover, methylation levels of UNC5C and UNC5D were independent predictors of CRC progression-free (P = 0.001, P = 0.003, respectively) and overall survival (P = 0.008, P = 0.004, respectively). Conclusions: Hypermethylation of UNC5C and UNC5D mediates the repression and has promising diagnostic and prognostic values in CRC.
1 January 2022 in SSRN Electronic Journal
Background: Noninvasive biomarkers for the assessment of tumor response in breast cancer (BCa) are essential for optimized therapeutic decision-making. We evaluated the potential of soluble Periostin (POSTN) in circulating as a novel biomarker for chemotherapy efficacy monitoring. Methods: In prevalence assessment, the correlation between the level of soluble POSTN and tumor volume, as well as TNM stages of BCa was verified. And in longitudinal assessment, advanced BCa patients receiving Her2-targeted or non-targeted chemotherapy were enrolled. Soluble POSTN, together with CA153 or CEA, were determined in serum collected at different time points (C0, C2 and C4) by enzyme linked immunosorbent assay (ELISA) or electrochemiluminescence immunoassays. Then we compared the performances of markers in recapitulating the chemotherapy efficacy assessed by imaging. Findings: Soluble POSTN levels were significantly associated with tumor volume and TNM stages of BCa, and its dynamics could recapitulate the early chemotherapy efficacy much better than that of CA153 and CEA. Moreover, further analysis indicated that, for early partial response, the monitoring efficiency of soluble POSTN with high baseline (above 17.05 ng/mL) was significantly higher than that of with low baseline. A strong consistency of POSTN response was observed in all four cases with progressive disease in long-term follow-up. And progression free survival analysis showed that patients experienced a significant early decrease of POSTN at C4 tended to obtain more benefits from the treatments. Interpretation: The current study suggests that soluble POSTN is an informative serum biomarker to complement the current clinical approaches for chemotherapy efficacy monitoring in advanced BCa. Funding: This study was supported by research grants from the National Natural Science Foundation of China (no. 81502519), the Natural Science Foundation of Tianjin (no. 19JCQNJC41200). Declaration of Interest: Authors declare no conflicts of interest for this article. Ethical Approval: All procedures performed in studies involving human participants were approved by the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital.
11 May 2026 in Cancer Biology & Medicine
Objective: Adaptive therapeutic tolerance frequently limits first-line lenvatinib efficacy in hepatocellular carcinoma (HCC). This study explored the C2H2-type zinc finger (ZNF) protein family (the largest class of transcription factors) and hypothesized that specific members of the ZNF protein family are hijacked by cancer cells to orchestrate pro-survival defenses against lenvatinib-induced ferroptosis. Methods: We implemented a hypothesis-driven integrative multi-omics strategy to identify clinically relevant ZNF drivers. The top candidate, ZNF768, was functionally investigated using lentiviral modulation in HCC cell lines and subcutaneous xenograft models. Mechanistic elucidation was performed through ChIP-qPCR, luciferase reporter assays, and upstream signaling pathway analysis. The therapeutic synergy of an AAV-shZNF768 vector combined with lenvatinib was evaluated in vivo. Results: ZNF768 was identified as a potent transcriptional driver of pro-survival programs in HCC; high expression correlated with poor patient prognosis. ZNF768 knockdown suppressed proliferation and robustly sensitized HCC cells to ferroptosis, which was marked by uncontrolled lipid peroxidation and GSH depletion. ZNF768 directly transactivated the SLC7A11 promoter, reinforcing the cellular antioxidant shield. We uncovered a paradoxical therapy-induced feedback loop in which lenvatinib inhibits AKT signaling, leading to EGR1 accumulation and transcriptional activation of ZNF768. This adaptive response limits the efficacy of lenvatinib. Consequently, disrupting this loop via ZNF768 knockdown synergizes with lenvatinib to trigger robust ferroptosis and profoundly suppress tumor growth in vivo. Conclusions: The EGR1-ZNF768-SLC7A11 axis constitutes a critical adaptive shield limiting lenvatinib efficacy in HCC. ZNF768 serves as a predictive biomarker and a high-value therapeutic target. Disrupting this axis offers a rational strategy to overcome therapeutic resistance and maximize the clinical potential of lenvatinib.